ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Justin Chakma sold 32,814 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $14.00, for a total value of $459,396.00. Following the completion of the sale, the insider now directly owns 203,566 shares of the company’s stock, valued at $2,849,924. This represents a 13.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Justin Chakma also recently made the following trade(s):
- On Wednesday, November 27th, Justin Chakma sold 25,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.39, for a total value of $359,750.00.
ARS Pharmaceuticals Stock Performance
Shares of NASDAQ SPRY opened at $14.51 on Friday. The stock has a market cap of $1.41 billion, a PE ratio of -28.45 and a beta of 0.90. The business has a fifty day moving average of $14.82 and a two-hundred day moving average of $12.01. ARS Pharmaceuticals, Inc. has a 52-week low of $4.76 and a 52-week high of $18.51.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
SPRY has been the subject of several research reports. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Leerink Partners raised their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, ARS Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $24.00.
Get Our Latest Research Report on SPRY
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
- Five stocks we like better than ARS Pharmaceuticals
- What is a SEC Filing?
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Comparing and Trading High PE Ratio Stocks
- 3 Penny Stocks Ready to Break Out in 2025
- How to Calculate Stock Profit
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.